BridgeBio Pharma (BBIO) Competitors $53.33 +2.15 (+4.20%) Closing price 09/18/2025 04:00 PM EasternExtended Trading$52.77 -0.56 (-1.05%) As of 04:19 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock BBIO vs. ONC, INSM, BNTX, TEVA, GMAB, SMMT, RDY, ASND, VTRS, and QGENShould you be buying BridgeBio Pharma stock or one of its competitors? The main competitors of BridgeBio Pharma include BeOne Medicines (ONC), Insmed (INSM), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Summit Therapeutics (SMMT), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Viatris (VTRS), and QIAGEN (QGEN). These companies are all part of the "pharmaceutical products" industry. BridgeBio Pharma vs. Its Competitors BeOne Medicines Insmed BioNTech Teva Pharmaceutical Industries Genmab A/S Summit Therapeutics Dr. Reddy's Laboratories Ascendis Pharma A/S Viatris QIAGEN BridgeBio Pharma (NASDAQ:BBIO) and BeOne Medicines (NASDAQ:ONC) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability, earnings and media sentiment. Is BBIO or ONC more profitable? BeOne Medicines has a net margin of -3.89% compared to BridgeBio Pharma's net margin of -329.25%. BridgeBio Pharma's return on equity of 0.00% beat BeOne Medicines' return on equity.Company Net Margins Return on Equity Return on Assets BridgeBio Pharma-329.25% N/A -85.69% BeOne Medicines -3.89%-1.22%-0.72% Which has more volatility & risk, BBIO or ONC? BridgeBio Pharma has a beta of 1.25, suggesting that its stock price is 25% more volatile than the S&P 500. Comparatively, BeOne Medicines has a beta of 0.21, suggesting that its stock price is 79% less volatile than the S&P 500. Which has preferable earnings & valuation, BBIO or ONC? BridgeBio Pharma has higher earnings, but lower revenue than BeOne Medicines. BeOne Medicines is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBridgeBio Pharma$235.81M43.23-$535.76M-$4.09-13.04BeOne Medicines$3.81B9.86-$644.79M-$1.73-198.20 Do analysts rate BBIO or ONC? BridgeBio Pharma currently has a consensus target price of $63.94, indicating a potential upside of 19.90%. BeOne Medicines has a consensus target price of $336.30, indicating a potential downside of 1.92%. Given BridgeBio Pharma's higher probable upside, research analysts clearly believe BridgeBio Pharma is more favorable than BeOne Medicines.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BridgeBio Pharma 0 Sell rating(s) 0 Hold rating(s) 17 Buy rating(s) 0 Strong Buy rating(s) 3.00BeOne Medicines 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders have more ownership in BBIO or ONC? 99.8% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 48.6% of BeOne Medicines shares are owned by institutional investors. 18.2% of BridgeBio Pharma shares are owned by company insiders. Comparatively, 6.6% of BeOne Medicines shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media prefer BBIO or ONC? In the previous week, BridgeBio Pharma had 1 more articles in the media than BeOne Medicines. MarketBeat recorded 12 mentions for BridgeBio Pharma and 11 mentions for BeOne Medicines. BridgeBio Pharma's average media sentiment score of 0.77 beat BeOne Medicines' score of 0.68 indicating that BridgeBio Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BeOne Medicines 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive SummaryBridgeBio Pharma beats BeOne Medicines on 11 of the 15 factors compared between the two stocks. Get BridgeBio Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for BBIO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BBIO vs. The Competition Export to ExcelMetricBridgeBio PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.78B$4.26B$5.78B$10.27BDividend YieldN/A1.33%5.74%4.64%P/E Ratio-13.0411.0576.4826.98Price / Sales43.2315.81536.54176.08Price / CashN/A7.0437.1760.63Price / Book-6.923.3013.756.37Net Income-$535.76M-$134.23M$3.29B$271.46M7 Day Performance4.14%-0.82%1.57%2.53%1 Month Performance9.04%4.27%6.83%9.42%1 Year Performance98.77%31.39%80.77%30.16% BridgeBio Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BBIOBridgeBio Pharma4.4535 of 5 stars$53.33+4.2%$63.94+19.9%+105.4%$9.78B$235.81M-13.04400ONCBeOne Medicines1.9072 of 5 stars$332.27+2.4%$330.89-0.4%N/A$35.55B$3.81B0.0011,000Analyst ForecastInsider TradeINSMInsmed3.2574 of 5 stars$143.14-1.9%$139.86-2.3%+100.2%$30.85B$363.71M-25.071,271Positive NewsBNTXBioNTech2.7653 of 5 stars$97.88+1.2%$135.80+38.7%-16.7%$23.26B$2.98B-61.176,772TEVATeva Pharmaceutical Industries2.7907 of 5 stars$18.90-5.2%$24.71+30.8%+3.1%$22.86B$16.54B-118.1336,830GMABGenmab A/S3.8265 of 5 stars$27.99+0.6%$39.25+40.2%+7.0%$17.85B$3.12B14.072,682Positive NewsSMMTSummit Therapeutics3.4094 of 5 stars$18.94flat$33.79+78.4%-21.7%$14.07B$700K-18.75110Positive NewsAnalyst ForecastRDYDr. Reddy's Laboratories2.4534 of 5 stars$14.64-0.2%$16.95+15.8%-6.0%$12.24B$3.81B22.1727,811ASNDAscendis Pharma A/S2.9673 of 5 stars$194.62-0.5%$244.36+25.6%+33.9%$11.97B$393.54M-37.721,017Positive NewsVTRSViatris1.4222 of 5 stars$9.60-3.6%$10.40+8.3%-17.1%$11.61B$14.74B-3.3132,000High Trading VolumeQGENQIAGEN4.4768 of 5 stars$45.39+0.2%$49.69+9.5%+3.0%$10.07B$1.98B26.825,765Positive News Related Companies and Tools Related Companies BeOne Medicines Alternatives Insmed Alternatives BioNTech Alternatives Teva Pharmaceutical Industries Alternatives Genmab A/S Alternatives Summit Therapeutics Alternatives Dr. Reddy's Laboratories Alternatives Ascendis Pharma A/S Alternatives Viatris Alternatives QIAGEN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BBIO) was last updated on 9/19/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis is the “End of Tesla” as we know it…Jeff has identified five of the past seven number-one performing tech stocks — before they took off. His Tesla...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BridgeBio Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BridgeBio Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
